Cover Image
市場調查報告書

中國製藥化學產品產業分析

China Chemical Pharmaceutical Industry Report, 2013-2016

出版商 ResearchInChina 商品編碼 304999
出版日期 內容資訊 英文 131 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國製藥化學產品產業分析 China Chemical Pharmaceutical Industry Report, 2013-2016
出版日期: 2014年06月04日 內容資訊: 英文 131 Pages
簡介

製藥化學產品分為配製(preparation)化學藥品部門與原料藥(API: active pharmaceutical ingredient)用化學藥品部門、毛利率前者較高。中國製藥化學產品產業、配製部門收益為5731億人民幣(2013年)、原料藥部門3820億人民幣(同)、利益比率前者為35∼40%、後者僅20%。中國是API用化學產品的一大生產國ザ、約生產1,600種原料藥、2013年總生產量答270萬9000噸。特別是盤尼西林、維他命、解熱鎮痛劑有著世界最大的生產規模、另外還原□的抑制劑、prils、沙坦類藥物也有很大的佔有率。但因市場集中度太低國內企業規模、競爭力有限。隨著環境規範增加競爭、許多原料藥製造商透過促進研究開發(R&D)轉換為配製製造商。

本報告針對中國製藥化學產品產業分析、提供全世界與中國最新業界動向及地區構造、全體生產量、需求量、貿易量、部門分類詳細動向、主要製造商檔案、今後業界動向預測調查。

第1章 製藥化學產品產業概況

  • 定義與分類
  • 相關產業

第2章 世界製藥化學產品產業動向

  • 現況
  • 需求量、供給量
    • 產品混合
    • 地區構造
  • 主要國家、地區
    • 北美
    • 歐洲
    • 新興國家
  • 發展動向
    • 面對困難的專利藥與有巨大可能性的學名藥
    • 促進成長的新興國家市場

第3章 中國製藥化學產品產業動向

  • 現況
    • 全體的現況
    • 製藥企業技術開發能力改善
    • 積極的企業收購、再組織化
  • 從業能力
  • 出口量、進口量
    • 配製用化學藥品
    • 原料藥(API)用化學藥品
  • 競爭環境

第4章 製藥化學產品市場各分類

  • 維他命
    • 現況
    • 競爭環境
    • 出口額、進口額
  • 抗生物質
  • 解熱鎮痛劑
  • 賀爾蒙
  • 抗腫瘤劑
  • 心血管、腦血管疾病用藥劑

第5章 中國主要原料藥(API)用化學產品製造商

  • Northeast Pharmaceutical Group Co., Ltd.
    • 企業檔案
    • 從業情況
    • 收益構造
    • 研究開發(R&D)
    • 未來展望
  • North China Pharmaceutical Co., Ltd.
  • Zhejiang Medicine Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Zhejiang NHU Co., Ltd.
  • Shandong Xinhua Pharmaceutical Company Limited
  • Shenzhen Hepalink Pharmaceutical Co., Ltd.
  • Zhejiang Xianju Pharmaceutical Co., Ltd.
  • Zhejiang Huahai Pharmaceutical Co., Ltd.
  • Tianjin Tianyao Pharmaceuticals Co., Ltd.

第6章 中國主要配製化學產品製造商

  • China Resources Double-Crane Pharmaceutical Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd.
  • Xizang Haisco Pharmaceutical Group Co., Ltd.
  • Livzon Pharmaceutical Group Inc.
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • Hainan Haiyao Co., Ltd.
  • Huaren Pharmaceutical Co., Ltd.
  • Humanwell Healthcare (Group) Co., Ltd.

第7章 結論與預測

  • 全體預測
    • 市場規模預測
    • 總收益金額預測
  • 企業動向

圖表一覽

目錄
Product Code: ZYM055

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than that of the API over the same period. In 2013, China chemical drug preparation industry and China API industry recorded revenue of RMB 573.1 billion and RMB 382 billion, with gross margin of 35%-40% and 20%, respectively.

China is a big producer of chemical APIs, capable of producing about 1,600 varieties of APIs. China ranks first worldwide in output of several bulk APIs including penicillins, vitamins and antipyretic analgesics, and holds a significant share of the featured APIs like statins, prils, sartans in the world. China produced 2.709 million tons of chemical APIs in 2013.

Although China is the world's leading chemical APIs supply region, the concentration of China chemical APIs industry is rather low due to numerous categories of APIs and limited overall strength of domestic enterprises, which occupy an important place only in single or a few categories of pharmaceuticals market. In addition, under the pressure of both environmental protection and industrial upgrading, many large APIs companies in the country are transforming into drug preparation companies through means such as R&D and acquisitions.

North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. are major suppliers of antibiotic and VC APIs in China, with supply of VS reaching around 20,000 tons each. In 2013, the two companies' total revenue from APIs and their revenue from drug preparation business reached RMB 5.695 billion and RMB 3.871 billion, respectively.

Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd. are the leading manufacturers of VE products around the globe, with raw materials (vital ingredients for the production of VE are limited raw materials: isophytol and trimethylhydroquinone) for VE being produced by themselves. However, the two companies' development is constrained due to a weak global demand for VE, of which Zhejiang Medicine reported revenue of RMB 4.915 billion from pharmaceutical business (APIs+ preparation), down 6.3% year on year.

Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. are the key suppliers of featured APIs in China, of which the former specializes in antineoplastic and cardiovascular products, and the latter, which obtains three certificates from EDQM in 2013, is a major global supplier of prils and sartans APIs. In 2013, the two companies' total revenues from APIs and drug preparation business were RMB 3.226 billion and RMB 2.272 billion, rising by 19.5% and 14.7% from the previous year, respectively.

Zhejiang Xianju Pharmaceutical Co., Ltd. and Tianjin Tianyao Pharmaceuticals Co., Ltd. are the leading suppliers of hormone APIs, of which the former has been aggressively expanding into downstream drug preparation business. In the context of stricter environmental standards and rising costs of raw materials, developing the downstream will undoubtedly ensure competitiveness of the company. In 2013, Xianju Pharmaceutical posted total revenue of RMB 2.233 billion from APIs and preparation business, up 16.2% against the prior year. Also in 2013, the company acquired three EDQM certificates for its APIs.

Revenue and Main Products of Major Chemical API Companies in China, 2012-2013

              Source: China Chemical Pharmaceutical Industry Report, 2013-2016,
                 ResearchInChina

China Chemical Pharmaceutical Industry Report, 2013-2016 highlights the following:

  • Development status quo, supply and demand, regional structure and trend of global chemical pharmaceutical industry;
  • Development status quo, competitive landscape, import and export and forecast of China chemical pharmaceutical industry;
  • Development status quo, competitive landscape and import and export of China chemical pharmaceutical segments, including vitamins, antibiotics, antipyretic analgesics, antineoplastics and cardiovascular and cerebrovascular;
  • Operation and prospects of 20 Chinese chemical APIs and preparation companies.

Table of Contents

1. Overview of Chemical Pharmaceutical Industry

  • 1.1. Definition and Classification
  • 1.2. Industry Chain

2. Development of Global Chemical Pharmaceutical Industry

  • 2.1. Status Quo
  • 2.2. Supply and Demand
    • 2.2.1. Product Mix
    • 2.2.1. Regional Structure
  • 2.3. Major Countries and Regions
    • 2.3.1. North America
    • 2.3.2. Europe
    • 2.3.3. Emerging Countries
  • 2.4. Development Trends
    • 2.4.1. Proprietary Drugs in Trouble, Generic Drugs with Great Potential
    • 2.4.2. Emerging Countries Being Growth Engines

3. Development of China Chemical Pharmaceutical Industry

  • 3.1. Status Quo
    • 3.1.1. Overall Conditions
    • 3.1.2. Improvement in Pharmaceutical Innovation Capability
    • 3.1.3. Active Merger and Reorganization of Pharmaceutical Companies
  • 3.2. Operating Capability
  • 3.3. Import and Export
    • 3.3.1. Chemical Preparations
    • 3.3.2. Chemical APIs
  • 3.4. Competitive Landscape

4. China Chemical Pharmaceutical Market Segments

  • 4.1. Vitamins
    • 4.1.1. Status Quo
    • 4.1.2. Competitive Landscape
    • 4.1.3. Import and Export
  • 4.2. Antibiotics
    • 4.2.1. Status Quo
    • 4.2.2. Competitive Landscape
    • 4.2.3. Import and Export
  • 4.3. Antipyretic Analgesics
    • 4.3.1. Status Quo
    • 4.3.2. Competitive Landscape
    • 4.3.3. Import and Export
  • 4.4. Hormones
    • 4.4.1. Status Quo
    • 4.4.2. Competitive Landscape
    • 4.4.3. Import and Export
  • 4.5. Anti-tumor
    • 4.5.1. Status Quo
    • 4.5.2. Competitive Landscape
  • 4.6. Cardiovascular and Cerebrovascular
    • 4.6.1. Status Quo
    • 4.6.2. Competitive Landscape

5. Key Chinese Chemical APIs Manufacturers

  • 5.1. Northeast Pharmaceutical Group Co., Ltd.
    • 5.1.1. Profile
    • 5.1.2. Operation
    • 5.1.3. Revenue Structure
    • 5.1.4. R&D
    • 5.1.5. Prospects
  • 5.2. North China Pharmaceutical Co., Ltd.
    • 5.2.1. Profile
    • 5.2.2. Operation
    • 5.2.3. Revenue Structure
    • 5.2.4. R&D
    • 5.2.5. Prospects
  • 5.3. Zhejiang Medicine Co., Ltd.
    • 5.3.1. Profile
    • 5.3.2. Operation
    • 5.3.3. Revenue Structure
    • 5.3.4. Investment and R&D
    • 5.3.5. Forecast
  • 5.4. Zhejiang Hisun Pharmaceutical Co., Ltd.
    • 5.4.1. Profile
    • 5.4.2. Operation
    • 5.4.3. Revenue Structure
    • 5.4.4. R&D
    • 5.5.5. Prospects
  • 5.5. Zhejiang NHU Co., Ltd.
    • 5.5.1. Profile
    • 5.5.2. Operation
    • 5.5.3. Revenue Structure
    • 5.5.4. R&D
    • 5.5.5. Prospects
  • 5.6. Shandong Xinhua Pharmaceutical Company Limited
    • 5.6.1. Profile
    • 5.6.2. Operation
    • 5.6.3. Revenue Structure
    • 5.6.4. R&D
    • 5.6.5. Prospects
  • 5.7. Shenzhen Hepalink Pharmaceutical Co., Ltd.
    • 5.7.1. Profile
    • 5.7.2. Operation
    • 5.7.2. Revenue Structure
    • 5.7.4. R&D
    • 5.7.5. Prospects
  • 5.8. Zhejiang Xianju Pharmaceutical Co., Ltd.
    • 5.8.1. Profile
    • 5.8.2. Operation
    • 5.8.3. Revenue Structure
    • 5.8.4. R&D
    • 5.8.5. Prospects
  • 5.9. Zhejiang Huahai Pharmaceutical Co., Ltd.
    • 5.9.1. Profile
    • 5.9.2. Operation
    • 5.9.3. Revenue Structure
    • 5.9.4. R&D
    • 5.9.5. Forecast
  • 5.10. Tianjin Tianyao Pharmaceuticals Co., Ltd.
    • 5.10.1. Profile
    • 5.10.2. Operation
    • 5.10.3. Revenue Structure
    • 5.10.3. Investment and R&D
    • 5.10.4. Prospects

6. Key Chinese Chemical Preparation Manufacturers

  • 6.1. China Resources Double-Crane Pharmaceutical Co., Ltd.
    • 6.1.1. Profile
    • 6.1.2. Operation
    • 6.1.3. Revenue Structure
    • 6.1.4. Investment and R&D
    • 6.1.5. Prospects
  • 6.2. Jiangsu Hengrui Medicine Co., Ltd.
    • 6.2.1. Profile
    • 6.2.2. Operation
    • 6.2.3. Revenue Structure
    • 6.2.4. R&D and Investment
    • 6.2.5. Prospects
  • 6.3. Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd.
    • 6.3.1. Profile
    • 6.3.2. Operation
    • 6.3.3. Revenue Structure
    • 6.3.4. R&D and Investment
  • 6.4. Xizang Haisco Pharmaceutical Group Co., Ltd.
    • 6.4.1. Profile
    • 6.4.2. Operation
    • 6.4.3. Revenue Structure
    • 6.4.4. Investment and R&D
    • 6.4.5. Prospects
  • 6.5. Livzon Pharmaceutical Group Inc.
    • 6.5.1. Profile
    • 6.5.2. Operation
    • 6.5.3. Revenue Structure
    • 6.5.4. Prospects
  • 6.6. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
    • 6.6.1. Profile
    • 6.6.2. Operation
    • 6.6.3. Revenue Structure
    • 6.6.4. R&D and Investment
    • 6.6.5. Prospects
  • 6.7. Jiangsu Nhwa Pharmaceutical Co., Ltd.
    • 6.7.1. Profile
    • 6.7.2. Operation
    • 6.7.3. Revenue Structure
    • 6.7.4. R&D
    • 6.7.5. Prospects
  • 6.8. Hainan Haiyao Co., Ltd.
    • 6.8.1. Profile
    • 6.8.2. Operation
    • 6.8.3. Revenue Structure
    • 6.8.4. R&D
    • 6.8.5. Prospects
  • 6.9. Huaren Pharmaceutical Co., Ltd.
    • 6.9.1. Profile
    • 6.9.2. Operation
    • 6.9.3. Revenue Structure
    • 6.9.4. Investment and R&D
    • 6.9.5. Prospects
  • 6.10. Humanwell Healthcare (Group) Co., Ltd.
    • 6.10.1. Profile
    • 6.10.2. Operation
    • 6.10.3. Revenue Structure
    • 6.10.4. Investment and R&D
    • 6.10.5. Prospects

7. Conclusion and Forecast

  • 7.1. Overall
    • 7.1.1. Market Size Forecast
    • 7.1.2. Profit Forecast
  • 7.2. Companies

Selected Charts:

  • Classification of Sub-sectors of China Chemical Pharmaceutical Industry
  • Profit Distribution of Chemical Pharmaceutical Industry
  • Size and YoY Growth Rate of Global Pharmaceuticals Market, 2003-2013
  • M&A Transaction Value in Global Pharmaceutical Industry, 2013
  • Global Top10 Mergers and Acquisitions in Pharmaceutical Industry, 2013
  • Number of New Drugs Approved by FDA, 2010-2013
  • New Drugs Approved by FDA and Sales, 2013
  • Blockbuster Drugs and Sales of 15 Large Global Pharmaceutical Companies, 2013
  • Sales Proportion of Global Generic Drugs, 2008-2013
  • Regional Distribution of Global Pharmaceutical Industry
  • Size and YoY Growth Rate of Global Pharmaceuticals Market by Country and Region, 2012
  • Proportion of Spending on Health Care to GDP in the U.S. and Canada, 1995-2012
  • Pharmaceuticals Sales in the United States, 2010-2012
  • Proportion of Spending on Health Care to GDP in Britain and France, 1995-2012
  • Pharmaceuticals Sales in Western Europe, 2010-2012
  • Pharmaceuticals Sales in Emerging Countries, 2010-2012
  • Contributions of Emerging Countries to Global Pharmaceuticals Sales Growth, 2010-2012
  • Real GDP Growth Rates of China, U.S., Britain and India, 2000-2012
  • Total Output Value and % of GDP of China Chemical Pharmaceutical Industry, 2010-2013
  • Comparison of Revenue from China Chemical APIs and Preparation Industries, 2010-2013
  • Output of Chemical APIs in China, 2007-2013
  • Pharmaceuticals Approved for Marketing in China, 2013
  • Revenue and Profit of China Chemical Preparation Industry, 2010-2013
  • Revenue and Profit of China Chemical APIs Industry, 2010-2013
  • Gross Margin of China Chemical Preparation and Chemical APIs Industry, 2010-2013
  • Import and Export Value of Chemical APIs in China, 2010-2013
  • Export Value and YoY Growth Rate of Featured APIs in China, 2010-2013
  • Regional Distribution of China's Chemical API Export by Value, 2013
  • Chemical Pharmaceuticals Purchase Amount Breakdown of China's Hospitals by Disease Pattern, 2012
  • Output and % of Vitamin in Export Volume in China, 2010-2013
  • Major Vitamin C Companies and Their Output in China, 2012
  • Major Vitamin E Companies and Their Output in China, 2012
  • Export Volume and Value and Average Price of China's Vitamins, 2009-2013
  • Proportion of Export Volume of China's Vitamins by Product, 2008-2013
  • Export Destinations of China's Vitamins, 2013
  • Import Volume and Value and Average Price of Vitamins in China, 2010-2013
  • Proportion of Import Volume of Vitamins in China by Product, 2008-2013
  • Sources of Imported Vitamins in China, 2013
  • Output of Main Antibiotic APIs in China, 2012
  • Output of Main Antibiotic Preparations in China, 2012
  • Manufacturers and Output of Main Antibiotic APIs in China, 2012
  • Import Volume and Value of Antibiotics in China, 2008-2013
  • Export Volume and Value of Antibiotics in China, 2008-2013
  • Output and Export Volume of Antipyretic Analgesics APIs in China, 2012
  • Export Volume of Antipyretic Analgesics APIs in China, 2012
  • Export Structure of Antipyretic Analgesics APIs in China by Volume, 2012
  • Hormone Drugs Output in China, 2010-2012
  • Output of Main Hormone APIs in China, 2012
  • Export Volume and Value of Hormone Products in China, 2013
  • Purchase Amount and Proportion of Main Antineoplastic and Immunoregulatory Drugs in Typical Hospitals of 22 Cities in China, 2012
  • Purchase Amount and Proportion of Main Cardiovascular System Drugs in Typical Hospitals of 22 Cities in China, 2012
  • Revenue and Net Income of Northeast Pharmaceutical, 2010-2013
  • Output and Export Volume of VC Series Products of Northeast Pharmaceutical, 2011-2012
  • Operating Revenue of Northeast Pharmaceutical by Product, 2010-2013
  • Operating Revenue of Northeast Pharmaceutical by Region, 2010-2013
  • Revenue and Net Income of Northeast Pharmaceutical, 2013-2016E
  • Output and Export Volume of Some APIs of North China Pharmaceutical, 2012
  • Revenue and Net Income of North China Pharmaceutical, 2009-2013
  • Operating Revenue of North China Pharmaceutical by Product, 2009-2013
  • Operating Revenue of North China Pharmaceutical by Region, 2009-2013
  • R&D Costs and % of Revenue of North China Pharmaceutical, 2011-2013
  • Revenue and Net Income of North China Pharmaceutical, 2013-2016E
  • Output and Export Volume of Some APIs of Zhejiang Medicine, 2012
  • Revenue and Net Income of Zhejiang Medicine, 2009-2013
  • Revenue of Zhejiang Medicine by Product, 2009-2013
  • Revenue of Zhejiang Medicine by Region, 2009-2013
  • R&D Costs and % of Revenue of Zhejiang Medicine, 2011-2013
  • Revenue and Net Income of Zhejiang Medicine, 2013-2016E
  • Revenue and Net Income of Zhejiang Hisun Pharmaceutical, 2010-2013
  • Operating Revenue of Zhejiang Hisun Pharmaceutical by Product, 2009-2013
  • Operating Revenue of Zhejiang Hisun Pharmaceutical by Region, 2009-2013
  • R&D Costs and % of Revenue of Zhejiang Hisun Pharmaceutical, 2010-2013
  • Revenue and Net Income of Zhejiang Hisun Pharmaceutical, 2013-2016E
  • Revenue and Net Income of Zhejiang NHU Co., Ltd., 2009-2013
  • Operating Revenue of Zhejiang NHU Co., Ltd. by Product, 2010-2013
  • Operating Revenue of Zhejiang NHU Co., Ltd. by Region, 2010-2013
  • R&D Costs and % of Revenue of Zhejiang NHU Co., 2010-2014
  • Revenue and Net Income of Zhejiang NHU Co., 2013-2016E
  • Revenue and Net Income of Shandong Xinhua Pharmaceutical, 2009-2013
  • Operating Revenue of Shandong Xinhua Pharmaceutical by Product, 2010-2013
  • Main Products and % of Revenue of Shandong Xinhua Pharmaceutical, 2013
  • Revenue and Net Income of Shandong Xinhua Pharmaceutical, 2013-2016E
  • Revenue and Net Income of Shenzhen Hepalink Pharmaceutical, 2009-2013
  • Operating Revenue of Shenzhen Hepalink Pharmaceutical by Product, 2009-2013
  • Operating Revenue of Shenzhen Hepalink Pharmaceutical by Region, 2009-2013
  • R&D Costs and % of Revenue of Shenzhen Hepalink Pharmaceutical, 2009-2013
  • Revenue and Net Income of Zhejiang Xianju Pharmaceutical, 2009-2013
  • Operating Revenue of Zhejiang Xianju Pharmaceutical by Product, 2009-2013
  • Operating Revenue of Zhejiang Xianju Pharmaceutical by Region, 2009-2013
  • R&D Costs and % of Revenue of Zhejiang Xianju Pharmaceutical, 2010-2013
  • Revenue and Net Income of Zhejiang Xianju Pharmaceutical, 2013-2016E
  • Revenue and Net Income of Zhejiang Huahai Pharmaceutical, 2009-2013
  • Revenue of Zhejiang Huahai Pharmaceutical by Product, 2009-2013
  • Revenue of Zhejiang Huahai Pharmaceutical by Region, 2010-2013
  • R&D Costs and % of Revenue of Zhejiang Huahai Pharmaceutical, 2011-2013
  • Revenue and Net Income of Zhejiang Huahai Pharmaceutical, 2013-2016E
  • Revenue and Net Income of Tianjin Tianyao Pharmaceuticals, 2010-2013
  • Revenue of Tianjin Tianyao Pharmaceuticals by Product, 2010-2013
  • Revenue of Tianjin Tianyao Pharmaceuticals by Region, 2010-2013
  • R&D Costs and % of Revenue of Tianjin Tianyao Pharmaceuticals, 2013
  • Investment Projects of Tianjin Tianyao Pharmaceuticals, 2013
  • Revenue and Net Income of Tianjin Tianyao Pharmaceuticals, 2013-2016E
  • Revenue and Net Income of China Resources Double-Crane Pharmaceutical, 2010-2013
  • Revenue Structure of China Resources Double-Crane Pharmaceutical by Sector, 2010-2013
  • Gross Margin of China Resources Double-Crane Pharmaceutical by Product, 2013
  • Revenue of China Resources Double-Crane Pharmaceutical by Region, 2010-2013
  • Construction Projects Invested by China Resources Double-Crane Pharmaceutical, 2013
  • R&D Expenditure Structure of China Resources Double-Crane Pharmaceutical, 2013
  • Revenue and Net Income of China Resources Double-Crane Pharmaceutical, 2013-2016E
  • Revenue and Net Income of Jiangsu Hengrui Medicine, 2010-2013
  • Operating Revenue of Jiangsu Hengrui Medicine by Product, 2010-2013
  • R&D Expenditure of Jiangsu Hengrui Medicine, 2013
  • Progress of Investment Projects of Jiangsu Hengrui Medicine as of 2013
  • Revenue and Net Income of Jiangsu Hengrui Medicine, 2013-2016E
  • Revenue and Net Income of Harbin Pharm. Group Sanjing Pharmaceutical Shareholding, 2010-2013
  • Operating Revenue of Harbin Pharm. Group Sanjing Pharmaceutical Shareholding by Product, 2010-2013
  • R&D Expenditure of Harbin Pharm. Group Sanjing Pharmaceutical Shareholding, 2013
  • Revenue and Net Income of Xizang Haisco Pharmaceutical, 2010-2013
  • Revenue and Gross Margin of Xizang Haisco Pharmaceutical by Product, 2013
  • Revenue of Xizang Haisco Pharmaceutical by Region, 2010-2013
  • Investment Projects of Xizang Haisco Pharmaceutical, 2013
  • R&D Expenditure of Xizang Haisco Pharmaceutical, 2010-2013
  • Revenue and Net Income of Xizang Haisco Pharmaceutical, 2013-2016E
  • Revenue and Net Income of Livzon Pharmaceutical Group, 2008-2013
  • Operating Revenue of Livzon Pharmaceutical Group by Product, 2008-2013
  • Operating Revenue of Livzon Pharmaceutical Group by Region, 2008-2013
  • Revenue and Net Income of Livzon Pharmaceutical Group, 2013-2016E
  • Revenue and Net Income of Shanghai Fosun Pharmaceutical, 2008-2013
  • Operating Revenue of Shanghai Fosun Pharmaceutical by Product, 2008-2013
  • Operating Revenue of Shanghai Fosun Pharmaceutical by Region, 2008-2013
  • R&D Costs and % of Revenue of Shanghai Fosun Pharmaceutical, 2008-2013
  • Revenue and Net Income of Shanghai Fosun Pharmaceutical, 2013-2016E
  • Revenue and Net Income of Jiangsu Nhwa Pharmaceutical, 2009-2013
  • Revenue of Jiangsu Nhwa Pharmaceutical by Product, 2009-2013
  • R&D Costs and % of Revenue of Jiangsu Nhwa Pharmaceutical, 2010-2013
  • Revenue and Net Income of Jiangsu Nhwa Pharmaceutical, 2013-2016E
  • Revenue and Net Income of Hainan Haiyao, 2009-2013
  • Operating Revenue of Hainan Haiyao by Product, 2009-2013
  • R&D Costs and % of Revenue of Hainan Haiyao, 2011-2013
  • Revenue and Net Income of Hainan Haiyao, 2013-2016E
  • Revenue and Net Income of Huaren Pharmaceutical, 2010-2013
  • Revenue of Huaren Pharmaceutical by Product, 2010-2013
  • Gross Margin of Huaren Pharmaceutical by Product, 2010-2013
  • Revenue of Huaren Pharmaceutical by Region, 2013
  • Investment Projects of Huaren Pharmaceutical, 2013
  • Mergers and Acquisitions Conducted by Huaren Pharmaceutical, 2013
  • R&D Expenditure of Huaren Pharmaceutical, 2011-2013
  • Revenue and Net Income of Huaren Pharmaceutical, 2013-2016E
  • Revenue and Net Income of Humanwell Healthcare, 2010-2013
  • Revenue and Gross Margin of Humanwell Healthcare by Product, 2013
  • Revenue of Humanwell Healthcare by Region, 2010-2013
  • Project Investment of Humanwell Healthcare, 2013
  • Equity Investment of Humanwell Healthcare, 2013
  • Revenue and Net Income of Humanwell Healthcare, 2013-2016E
  • Number of People Aged 65 and Over and Percentage of Total Population, 2004-2013
  • Revenue of Chemical Preparations and Chemical APIs in China, 2010-2016E
  • Gross Margin of Chemical Preparations and Chemical APIs in China, 2010-2016E
  • Revenue and Main Products of Key Chemical APIs Companies in China, 2013
  • Revenue of Key Chemical Preparations Companies in China, 2013
Back to Top